Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oasmia Pharmaceutical AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.00.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Oasmia Pharmaceutical AB (publ). This N/A consensus rating has held steady for over two years.
Oasmia Pharmaceutical AB (publ)
Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.